IAN4 Antibody
Description
Table 1: Key Applications of IAN4 Antibody in Published Studies
Role in T Cell Survival
-
Mitochondrial integrity: IAN4 maintains mitochondrial membrane potential (Δψ<sub>m</sub>). T cells from Ian4⁻/⁻ rats exhibit 40% lower Δψ<sub>m</sub> than WT, reversible with cyclosporin A .
-
Apoptosis regulation: IAN4 deficiency causes spontaneous T cell apoptosis (35–50% subdiploid DNA in Ian4⁻/⁻ vs. <10% in WT) .
-
BCR/ABL dependency: IAN4 expression is induced by wild-type BCR/ABL but not mutant forms (e.g., p185ΔBCR, p210ΔSH2) .
Implications in Disease Models
-
Autoimmune diabetes: Ian4⁻/⁻ BBDP rats develop T cell lymphopenia and diabetes, linked to mitochondrial stress and chaperonin upregulation (e.g., Hsp60) .
-
Therapeutic potential: Caspase-8 inhibition or T cell activation rescues Ian4⁻/⁻ T cells, suggesting pathways to mitigate IAN4-related apoptosis .
Limitations and Future Directions
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Q&A
Basic Research Questions
What experimental approaches validate IAN4 antibody specificity in hematopoietic cell studies?
-
Perform western blotting with BCR/ABL-positive vs. mutant transfectants (e.g., p210ΔSH2 or BCR/ABL TM mutants) to confirm antibody reactivity correlates with endogenous IAN4 expression levels .
-
Use immunocytochemistry with mitochondrial markers (e.g., MitoTracker) to verify subcellular localization patterns match IAN4's outer mitochondrial membrane residency .
How does IAN4 expression correlate with BCR/ABL oncogenic activity?
Experimental validation requires:
-
Quantitative RT-PCR in isogenic cell lines expressing WT vs. kinase-dead BCR/ABL mutants
-
Dose-response analysis using tyrosine kinase inhibitors (e.g., imatinib)
Data shows IAN4 mRNA levels decrease by >80% in BCR/ABL TM (Y177F/R552L/Y793F) mutants compared to WT .
What controls are essential for IAN4 detection in mitochondrial fractions?
Advanced Research Questions
How to resolve contradictions in IAN4 expression data across studies?
Common methodological considerations:
-
Cell model variations: IAN4 is undetectable in v-src/ras-transformed lines but highly expressed in BCR/ABL+ 32D cells
-
Technical factors: Northern blot sensitivity vs. qPCR dynamic range
What experimental designs assess IAN4's GTPase function?
A robust protocol includes:
-
Recombinant IAN4 purification with N-terminal GTP-binding domain (residues 68-150)
-
Nitrocellulose filtration assays using [α-32P]GTP
Key finding: IAN4-HA immunoprecipitates show 2.5× increased GTP binding vs. controls (p<0.01) .
How to investigate IAN4's role in mitochondrial apoptosis pathways?
| Approach | Readout | Key Insight from Literature |
|---|---|---|
| BH3 profiling | Cytochrome c release | IAN4 co-localizes with Bcl-2 family proteins |
| Metabolic flux analysis | Oxygen consumption rates (OCR) | GTP-binding mutants alter Complex IV activity |
Methodological Challenges
7. Addressing low antibody signal in IAN4 membrane fractionation studies
Troubleshooting guide:
| Issue | Solution | Validation |
|---|---|---|
| Protein solubility | Use 1% digitonin extraction | Compare Porin vs. COX IV recovery |
| Epitope accessibility | Trypsin pretreatment of mitochondria | Monitor HA-tag cleavage by western |
8. Standardizing IAN4 quantification across hematopoietic lineages
Implement:
-
Normalization to mitochondrial DNA content (e.g., ND1/COX1 qPCR)
-
Flow cytometry with dual staining (IAN4 antibody + TMRE mitochondrial dye)
